Target intelligence / Profile preview

Bacterial microbiome

Molecular classification
Other (community/ecosystem, not a single molecule or protein)
01

Overview

The bacterial microbiome refers to the collective community of all bacterial species inhabiting a particular environment—most commonly discussed in reference to human body sites such as the gut, skin, oral cavity, etc.[1][4]. This ecosystem plays essential roles in digestion, metabolism, immune system development and regulation, protection against pathogens through colonization resistance, synthesis of vitamins/metabolites important for host health—and its disruption has been linked to numerous diseases including infections, inflammatory conditions like IBD and allergies,[2][3], metabolic disorders,[7], cancer,[6], neurological conditions,[6], among others. While individual bacterial strains within this community can be considered therapeutic targets—for example by using probiotics or engineered commensals—the "bacterial microbiome" itself is not a single molecular target like an enzyme or receptor. Instead it represents an ecological entity whose overall composition/function can be modulated therapeutically using approaches such as fecal transplantation,[9], probiotics/prebiotics,[9], phage therapy targeting specific members,[2], synthetic biology-driven engineering,[3]. Because it is not a discrete molecule/protein/receptor/transporter/enzyme/transcription factor/etc., listing it as a drug target is scientifically inaccurate. In summary: The term "bacterial microbiome" describes an entire living ecosystem rather than an individual molecular target. It should not be classified alongside canonical drug targets such as receptors or enzymes. --- Key points regarding structured data extraction: • The entry “Bacterial microbiome” does not represent a canonical therapeutic target but rather an ecological concept encompassing many potential targets. • If you require information about specific druggable components within this ecosystem—such as particular bacterial strains/species/enzymes/receptors—those should be specified individually. • For structured databases focused on molecular targets suitable for pharmacological intervention (“target” meaning receptor/enzyme/etc.), “Bacterial microbiome” would generally be flagged as incorrect/inapplicable.

Other names
Human bacterial microbiomeGut bacterial microbiomeMicrobiota (when referring specifically to bacteria)Commensal bacteria (context-dependent)
02

Mechanism of action

Mechanisms depend on intervention but may include: - Restoration of microbial balance via colonization with beneficial species/probiotics [9] - Suppression or elimination of pathogenic species via phages or engineered microbes [2] - Modulation of immune responses through microbial metabolites and cell signaling [3][6]

03

Biological functions

Digestion and nutrient absorptionImmune system modulationColonization resistance against pathogensMetabolism of xenobiotics and drugsSynthesis of vitamins and bioactive compounds
04

Disease associations

Infection (protection against or facilitation of)Inflammation (e.g., inflammatory bowel disease)Cancer (modulation of therapy response, e.g., immunotherapy efficacy)Metabolic diseases (obesity, diabetes)Neurological diseases (multiple sclerosis, neurodevelopmental disorders)
05

Safety considerations

Therapeutic challenges include unpredictable engraftment/survival of introduced microbespotential transfer of antibiotic resistance genesrisk from introducing unknown pathogens with FMTunintended immune reactionslack of specificity when targeting broad communities rather than individual species
06

Interacting drugs

Probiotics (*Lactobacillus rhamnosus* GG, *Bifidobacterium lactis*, *B. breve*, etc.)

3 more in the full profile.

07

Biomarkers

No universal biomarkers for the entire "bacterial microbiome," but changes in composition/diversity can serve as biomarkers for disease risk/response; stool-based microbial signatures are used for liver fibrosis/cirrhosis diagnosis [7].

Beyond the preview

Go deeper on Bacterial microbiome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial microbiome.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call